Ulcerative colitis (UC) is a chronic, relapsing and debilitating idiopathic inflammation, with variable and complex pathophysiologies. Our objective was to elucidate patterns of gene expression underlying the progression of UC disease. Single endoscopic pinch FFPE biopsies (n = 41) were sampled at both active and inactive stages at the same site in individual UC patients and compared with each other and with non-inflammatory bowel disease healthy controls. Gene expression results were validated by quantitative reverse transcriptase-PCR (QRT-PCR), and results at the protein level were validated by immunohistochemistry and western blot. Analysis of microarray results demonstrated that UC patients in remission display an intermediate gene expression phenotype between active UC patients and controls. It is clear that UC active site recovery does not revert fully back to a healthy control phenotype. Both UC active and inactive tissue displayed evidence, at both the gene expression and protein level, of a positive precancerous state as indicated by increases in the expression of Chitinase 3-Like-1, and the colorectal cancer metastasis marker MMP1. A key distinguishing feature between active and inactive UC, however, was the mobilization of marker genes and proteins for the Epithelial Mesenchymal Transition (EMT) pathway only in active UC. Analysis of the gene expression signatures associated with UC remission identified multiple pathways which appear to be permanently dysregulated in UC patients at formerly active sites in spite of clear histological recovery. Among these pathways, the EMT pathway was specifically up-regulated only in active UC emphasizing the potential for cancer progression in these patients.
and the severity of inflammation (5) . The exact pathophysiology of UC disease is unclear as it may involve either immune over or under responsiveness with environmental and genetic factors playing a modifying role as well (6) (7) (8) (9) . In order to reduce mortality and improve early detection of precancerous lesions, it is important to define a UC-specific molecular signature which, in addition to being of potential diagnostic and prognostic value, may also provide valuable information for the identification of therapeutic targets for the treatment of UC.
Recent microarray-based genome-wide gene expression studies of mucosal colonic biopsies have provided insight into the pathophysiological processes in active UC, demonstrating profound alteration of multiple immune, inflammatory, microbial and metabolic gene pathways (2, (10) (11) (12) (13) (14) (15) . Interestingly, the results from several of these studies have demonstrated the presence of a continuous inflammatory state found in inactive UC patient tissue (14, 16) . A pattern of distinctive genes, REG4, ABCG2, AQP8 and CHI3L1, have been shown to be differentially regulated when diseased samples from patients with active or inactive inflammation were compared with controls (2) . Direct comparison of active and inactive tissue samples in these studies may be confounded by the use of clinically different subgroups according to the anatomic site of involvement and disease behavior. In this study, we used active and inactive biopsies harvested at different time points but from the same anatomic site in patients in order to minimize patient-to-patient variability as well as variability arising from different anatomic sites.
A primary objective in this study was to first confirm, using exact site biopsies, the previous observations that UC patients in remission do not fully revert to a healthy phenotype (2, 17) . In this regard, we have identified biologically relevant gradients of gene expression which extend from healthy controls through inactive stages to active disease. We also identified important biological pathways that distinguish active UC from inactive UC and provide an insight into the molecular process which may lead directly to colon tissue dysplasia and CRC.
Results
Ulcerative colitis patients in remission do not fully revert to a healthy phenotype Genome-wide gene expression was analyzed in mucosal biopsies taken at the time of colonoscopy from 12 UC patients with active ulcerative colitis followed by inactive disease at the same site, and compared with 12 controls (Table 1 and Supplementary Material, Table S4 ). In addition to the 12 matched active/inactive samples, several additional samples were obtained from each condition over time, included a single repeat from the inactive group and four repeat time points for the active group. Principal component analysis (PCA) was performed using the complete gene expression data from all samples and used to generate a three-dimensional plot of the data (Fig. 1A ). Both active (red) and inactive (blue) UC were well separated from healthy control tissue (green) but were also clearly separated from each other into two groups. In addition, multiple instances of repeated active/remission cycles remained segregated with their clinically appropriate groups. These initial analysis results strongly suggested that our full data set contained large sets of genes that could differentiate between the active and inactive UC disease states as well as distinguishing both of those groups from healthy controls. The expression profiles between healthy and diseased tissue (Fig. 1B) were directly compared on a gene-by-gene basis. By comparing UC-active samples directly with controls, we identified 4145 genes that were significantly perturbed (2694 up-regulated genes; 1451 down-regulated genes) relative to controls (Fig. 1C) . By comparing UC-inactive samples directly to controls, we also identified 3210 genes that were significantly perturbed (2226 up-regulated genes; 984 down-regulated genes) relative to controls (Fig. 1C) . Of these genes, a significant number (∼60%) were shared between the active and inactive groups [1447 genes showed higher expression (Fig. 1D ) and 643 genes showed lower expression ( Fig. 1E) In order to investigate the biological functions involved in the groups of genes distinguishing UC active from UC inactive and from healthy controls, functional enrichment analysis was performed on lists of statistically significantly regulated genes (Fig. 1C) derived from the calculated comparisons. Significant genes were tested for category enrichment using gene sets derived from multiple biological pathways including those for inflammatory and immune responses, proliferation, adhesion and apoptosis, tumor and metastasis, nuclear receptors, cell junction and metabolism (Table 2 ). An increase in biological functions linked to cell inflammatory and immune responses was seen in both in active UC and inactive UC, suggesting the significant presence of a continuous inflammatory process in Table 2 ) on a gene by gene, sample by sample basis. From the heat map, a clear stepwise increase in average gene expression can be seen from healthy controls to UC inactive patients through to the active UC group. The average gene expression for each sample for the inflammatory response pathway as shown in Figure 2B quantitatively demonstrates this relationship, the statistical estimates reported in Figure 2C between the averages of each group show a significant difference with both active and inactive UC significantly up-regulated from controls (P < 2.4E − 15, and P < 1.9E − 10, respectively) and the UC active group is also significantly up-regulated relative to inactive UC (P < 1.3E − 02) (the P-values of t-test for all the tested pathways are shown in Table 2 ). Pathway analysis also revealed a large number of regulated genes involved in cell cycle, apoptosis, proliferation and cell adhesion. Once again, although both groups were up-regulated versus controls, active UC was consistently more highly regulated than inactive UC for these specific pathways (see individual pathway averages for each phenotypic group located at the right side of Table 2 ).
Evidence for UC as a precancerous disease
The expression of genes for biological functions related to tumor and metastasis were found to be up-regulated for both active and inactive UC patients (Table 2) . Strikingly, both up-and downregulated gene expression signatures derived directly from studies of CRC adenomas (18) were found to be significantly up-and down-regulated in a coordinate fashion in both active and nonactive UC patients relative to controls ( Table 1) . Both MMP1 and CHI3L1, members of the colorectal adenoma up-regulated pathway, showed a marked up-regulation in both UC active and inactive samples (Fig. 3, D1 and 2). Likewise, ABCG2, a member of the colorectal adenoma down-regulated pathway, was significantly down-regulated in UC active and UC remission samples compared with controls (Fig. 3, D3 ). These findings were confirmed by IHC staining in another independent COHORT 3 ( Table 1) , which include UC with dysplasia and colorectal carcinoma patients. Representative IHC images are shown in Figure 4 (scoring data are summarized in Supplementary Material, Table S2 ). Both MMP1 and CHI3L1 show an increased gradient of expression between healthy tissue, UC inactive, UC active, UC with dysplasia and CRC samples whereas ABCG2 shows decreased expression. As predicted from both the microarray and RT-PCR results (Fig. 3) , UC inactive samples display an intermediate between controls and active UC.
Epithelial mesenchymal transition marker genes distinguish active UC from inactive UC and control colon tissue
Pathways up-regulated only in active UC patients were identified which did not exhibit the typical intermediate phenotype in inactive UC patients otherwise so predominant throughout this study. These specific active pathways included genes for cell adhesion (Supplementary Material, Fig. S1 ) and the epithelial mesenchymal transition (EMT) pathway (Table 2 , Supplementary Material, Fig. S4 ). The EMT is a process of cellular dedifferentiation during which epithelial cells lose their cell polarity and cell-cell adhesion properties, and gain migratory and invasive properties as they progress to become mesenchymal cells. EMT gene expression plays a naturally benign physiological role in both development and wound healing but can also signal the initiation of metastasis in the progression of disseminated cancers (19) . Gene expression for the EMT pathway was shown to be enriched in active UC and but not in inactive UC or in normal controls by both functional enrichment analysis ( Table 2 , tumor and metastasis pathways; EMT, P < 2.6E − 08-UC active versus control; P < 1.8E − 05-UC active versus UC inactive) as well as by S4C ) and between phenotype groups (Supplementary Material, Fig. S4D ). This finding was particularly striking because we have already shown that, in general, UC active and inactive tissue share highly similar patterns of gene expression regulation (see above). The distinctive difference in the molecular phenotype between active UC and UC patients in remission for EMT genes suggests a key difference in the metastatic potential at active sites of ulceration in UC patients which may lead directly to the increased cancer risk for patients with active UC. The loss of E-cadherin from epithelial cells is considered to be a fundamental event in EMT conversion (20) . Conversely, the activation of vimentin is a potent marker for both the induction of cell motility and the repression of cytokeratin expression characteristic of the final phases of the epithelial to mesenchymal cell transition (21) . The expression of the E-cadherin and vimentin genes was tested by RT-PCR in independent COHORT 2 and shown to be significantly deregulated in active UC samples compared with UC in remission and non-IBD controls (Fig. 5A , P < 0.05). These changes were not evident in the UC inactive patients. The over-expression of vimentin in UC active patients was confirmed by 2-DGE, MALDI-TOF/TOF MS, and the increase of vimentin and the loss of E-cadherin in UC active patients by western blotting (Fig. 5B) . These results were further confirmed by immunohistochemistry in another independent COHORT 3, which include UC with dysplasia and colorectal carcinoma patients. Representative IHC images are shown in Figure 5C and D (scoring data are summarized in Supplementary Material, Table S3 ). Vimentin shows an increased expression in UC active and UC active with dysplasia compared with healthy tissue, but not in inactive UC or in inactive UC with dyspalsia. While E-cadherin shows decreased expression in UC active and UC active with dysplasia compared with healthy tissue, but not in inactive UC or in inactive UC with dyspalsia.
Vimentin gene expression was significantly increased (Planell; P < 4.4E − 06, Bjerrum; P < 2.5E − 03) in active UC compared with controls not in active UC (exclude Planell study, which used different definitions for remission UC and active UC) in two additional data sets in which the microarray gene expression profiles of colonic biopsies taken from the active sites and inactive sites of inflammation in ulcerative colitis patients and from non-inflammatory controls were examined [Planell et al. (2) and Bjerrum et al. (17)]. Similarly, E-cadherin gene expression was significantly decreased in active UC not inactive UC compared with controls (Planell; P < 5.3E − 04, Bjerrum; P < 0.04) (Supplementary Material, Fig. S3 ). These results taken together with our data reported here strongly suggest that tissue dedifferentiation is a general marker of active ulcerative colitis.
Discussion
In this study, we have shown that UC patients in inactive stages display a molecular phenotype intermediate between activestage UC and normal controls. We have also shown that there is a significant increase in the gene expression of markers of oncogenesis between active and inactive UC biopsies relative to healthy controls. Once again, the greatest increase (MMP1, CHI3L1), or decrease (ABCG2), in the expression of these genes at both the transcriptional and protein levels occurs in active UC with less but still significant differential expression occurring at former active sites in UC patients in remission. Finally, we show that up-regulation of the EMT pathway is specifically involved in the pathogenesis of the intestinal mucosa in patients with active UC. This finding provides a mechanistic explanation for the increase of cancer occurrence risk long associated with extensive UC disease of long duration (3, 22, 23) . Chronic UC inflammation actively promotes tissue dysplasia and increases the metastatic potential of the underlying dysregulated colonic mucosal epithelial tissue.
During active inflammation, a large number of tumor and metastasis associated genes are significantly dysregulated in UC patients. It is of interest that the three major biomarkers of oncogenesis selected for validation in this present study (MMP1, CHI3L1, ABCG2, Fig. 3 D1-3, Fig. 4) were previously identified by Sabates et al. (18) as hallmark changes in the progression of normal tissue to CRC and are also consistent with the data from two of the landmark microarray papers in IBD (2,17) (Supplementary Material, Fig. S2 ). MMP1 is a member of metaldependent enzymes family responsible for the degradation of extracellular matrix components (24) . The role of MMPs in CRC has been described (25, 26) . Numerous metalloproteinases, including MMP1, MMP3 and MMP7, are over-expressed in colorectal tumors (27) , and there is growing evidence that MMPs are involved in nearly every step of cancer development, including cell proliferation, apoptosis and angiogenesis (28, 29) . The expression of CHI3L1, an inflammation-associated molecule secreted from restricted cell types including colonic epithelial cells (CECs) and macrophages (30) , is enhanced in patients with colitis and colon cancer (31) . Elevated levels of CHI3L1 protein are detected in the colonic mucosa and sera of persons with active IBD but not inactive IBD (30) . As reported by Chen et al. (32) , enhanced CHI3L1 expression is a useful marker for predicting malignant transformation in patients with UC. These findings for the association of CH3L1 as a marker of oncogenesis in IBD are consistent with our results. Our data support the hypothesis that increased CHI3L1 expression in epithelial cells is strongly associated with inflammation-associated malignant transformation in active UC. Finally, ABCG2, also known as breast cancer resistance protein (BCRP/ABCG2), is a member of the ATP-binding cassette (ABC) transporter family, which is localized in the apical membrane of intestinal lumen. Previous studies have reported that the expression of ABCG2 is down-regulated in most human cancers (33) . The tumor-associated down-regulation of ABCG2 expression is also demonstrable in active UC and has been widely reported by both gene arrays and quantitative QRT-PCR (2, 11, 34, 35) , again, in close agreement with our own results.
This study has confirmed the presence of a continuous inflammatory state in inactive UC colonic mucosa. Contrary to a previous study (2) , the gene expression of markers of inflammation such as CXCL1, IL8, NFKBIZ and REG1A did not return to basal levels but remain significantly elevated in the mucosa of UC patients in remission, the discrepancy due perhaps to differences in the methods of tissue sample selection (Planell et al. (2) used previously involved mucosa segments from UC patients in remission, this study uses exact location matches in the same patient pre-and post-inflammation). An intermediate inflammatory state in UC patients in remission has also been found by others (17) , most notably for CCR7 and CCL19 cytokine markers of chronic inflammation. Furthermore, in addition to inflammatory pathways, we found that many of the significantly dysregulated genes in inactive UC belong to multiple pathways ( Table 2 ) that were similarly perturbed (differing only by degree) in patients with both active and inactive UC including pathways corresponding to the biological functions of cellular proliferation, angiogensisis and apoptosis, as well as for the cancer-related pathways previously discussed.
A subset of EMT associated genes were up-regulated only in active UC. The EMT represents a process of transition from a differentiated, polarized epithelial cell to a dedifferentiated Table 2. mesenchymal-like cell featuring a myofibroblast phenotype (36) . Epithelial cells display epithelial cell-type markers, including E-cadherin, and mesenchymal cells display mesenchymal cell-type markers such as vimentin (37, 38) . We validated the regulation of the EMT process in active UC by demonstrating the selective loss of E-cadherin and increase in vimentin at both the RNA and protein levels using a combination of QRT-PCR and immunohistochemistry (Fig. 5) . These results were consistent with the results from our previous study (39) of the active UC proteome with 2-DE and MALDI-TOF/TOF MS (Fig. 5, C1 ) and were further validated by western blot (Fig. 5, C2 ). All the results predict that the EMT process takes place in active UC and distinguishes active UC from both UC in remission and controls.
In conclusion, these data provide a rigorously characterized expression profile of the whole genome in the same patients with different stages of ulcerative colitis and as compared with controls. This study also demonstrates the presence of specific gradients of gene expression as measured from healthy controls through inactive to active disease and extends observations from previous studies related to finding permanent changes in colonic mucosal tissues resulting from chronic UC inflammation. Despite the presence of signatures of malignancy in both active and inactive UC disease (varying only by degree), up-regulation of markers of the EMT pathway takes place in exclusively in active UC and thus may serve as a useful marker of cancer risk assessment in UC patient tissue.
Materials and Methods

Patients and biopsy specimens
The institutional ethics committee approved all protocols, and all enrolled subjects gave their informed consent. UC diagnosis and disease activity was conducted by senior pathologists and physicians based on Matts score and Mayo-score. Active disease was defined as a Mayo score of ≥3 with at least one point in the bleeding sub-score and two points in the endoscopic sub-score, together with a histological score of ≥3 in any colonic segment. Inactive disease was defined as a Mayo score of ≤2, an endoscopic subscore of 0 and a histological score of ≤2. Intestinal biopsies were collected from the sigmoid colon or rectum of control healthy and UC patients. Active-stage UC biopsy samples were obtained from inflamed areas in UC patients; the biopsies of inactive stage were taken at the same sites of active inflammation in the same UC patient following healing. Control samples were obtained from normal colon tissue of healthy volunteers. 
RNA isolation
Three 5 µm sections per FFPE block were used for RNA isolation. RNA deparaffinisation, extraction and purification were performed according to the manufacturer's instructions using the AllPrep DNA/RNA FFPE Kit (Qiagen, Gaithersburg, MD, USA).
DASL microarray and data analysis
Whole-genome DASL (Illumina, USA) was performed as per manufacturer's instructions. Data were collected using the Illumina Genome Studio software. Raw and normalized data can be accessed from the Gene Expression Omnibus (GEO) database (40,41) (GSE53306). Details of data analysis are described in Supplementary Material.
Quantitative reverse transcription PCR (QRT-PCR)
QRT-PCR was carried out on cDNA obtained from total RNA using the cDNA Archive Kit according to the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). Probes and primers were designed to accommodate the shorter amplicon sizes (average size = 95 nucleotides) expected to be found in partially degraded FFPE RNA samples and were synthesized by Integrated DNA Technologies, Inc. (San Diego, CA, USA). QRT-PCR reactions were carried out in triplicate using the SYBR Green system on a HT7300 real-time PCR instrument (Applied Biosystems). Relative gene expressions were calculated by using the 2 −ΔΔCt method as described in Reference (42) . The ΔCt value of each sample was calculated using GAPDH as an endogenous control gene.
Immunostaining of intestinal samples
Biopsy specimens taken from a total of 53 patients (the 41 patients assayed by microarray as described plus 12 additional colorectal carcinoma patients) were subjected to IHC analysis, and scoring was performed independently by two investigators (Supplementary Material).
Protein separation and identification by 2DE and MALDI-TOF/TOF MS As previously described (39), the TCA-acetone precipitation method was adopted in the sample preparation of intestinal tissues. The extracted proteins were separated by two-dimensional gel electrophoresis (2-DE) with samples of UC tissue and normal tissue compared to identify the spots with significant changes in relative spot volume (>3-fold); differential spots were manually excised from gels and subjected to in-gel digestion with trypsin, followed by peptide identification using TOF/TOF MS (Supplementary Material).
Western blotting
As previously described (39) , proteins extracted from the biopsy specimens were resolved in 10% or 12% SDS-PAGE and electrotransferred onto PVDF membranes (350 mA for 1 h). All blots were scanned using Imagequant ECL system (GE, USA). The antibodies for Vimentin and E-cadherin were obtained from Santa Cruz.
